Skip to main content
. 2024 Mar 21;10(3):123–130. doi: 10.1159/000538295

Table 2.

Clinical details, ease of surgery score, and response to neoadjuvant systemic chemotherapy in 10 patients of SGC

S. No. Age/sex Lat./eyelid Primary/recurrent Previous surgery AJCC % reduction/RECIST Surgery planned EOS score/category TRT outcome and follow-up, months
before after NACT before after NACT
before after NACT
1 40/F RU Recurrent Tenzel’s flap T2CN0M0 T1c N0M0 75/PR Lid-sharing procedure Direct closure 10/7 2/1 Alive (77)
2 44/M RU Primary T3b N0M0 T2b N0M0 54.16/PR Lid-sharing procedure Hugh’s procedure 13/9 3/2 Alive (33)
3 42/M LU Recurrent Excision with direct closure T3c N0M0 T3c N0M0 88.7*/PR Lid-sharing procedure Cutler beard^ 16/12 3/3 Alive (35)
4 70/M LL Primary T4b N1M0 T4b N0M0 11.76/SD Exenteration Exenteration 17/16 3/3 ##Died of disease (27)
5 65/M RU Primary T4a N0M0 T3c N0M0 53.12/PR Exenteration Cutler beard 17/12 3/3 Lost to follow-up (26)
6 49/M RL Recurrent Tenzel’s flap T3c N0M0 T1c N0M0 CR Lid-sharing procedure Hugh’s procedure 17/12 3/3 Alive (32)
7 55/F RL Recurrent Tenzel’s flap T4a N0M0 T4a N0M0 >60* PR Exenteration Exenteration 20/20 3/3 Alive (31)
8 45/F RU Primary T4a N0M0 T4a N0M0 >90%*/PR Exenteration Reverse cutler beard 17/11 3/2 Alive (23)
9 60/F L Primary T3c N0M0 T2c N0M0 36.84/PR@ Lid-sharing procedure Direct closure 12/9 3/2 Died of unrelated cause (22)
10 57/F RU Recurrent Orbitotomy with tumour debulking T4a N0M0 T4a N0M0 >90%*, PR# Exenteration Exenteration 17/17 3/3 Alive (23)

*On imaging.

**All lid tissue that appeared to have post-tumour regression changes was removed.

$Orbital tumour disappeared completely, eyelid thickening reduced but persisted.

#Thickening of the upper eyelid persisted.

@Lid lengthening due to weight of the tumour allowed direct closure despite partial regression,

#Exenteration done in view of pathological confirmation of residual orbital tumour.

^More than 75% of length involved despite PR.

##Denied radicle LN dissection and EBRT.